Conditional Resolutions in the Amnog Early Benefit Assessment
نویسندگان
چکیده
منابع مشابه
Inclusion and Consideration of Patient Preferences in Amnog Early Benefit Assessments.
Patient perspective is becoming increasingly important in healthcare decision making. Patients should be involved as ‘end-users’ in the health technology assessment (HTA) processes to broaden the perspectives of the assessments and advice provided to decision makers1. Patients can provide information on their daily experience with disease, treatments and their needs, provide views on aspects no...
متن کاملEarly benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
Since 2011, Germany's Pharmaceutical Market Restructuring Act has mandated that all newly introduced drugs are subject to an assessment of their benefits in relation to a comparator, typically the current standard treatment. For drugs found to have some additional benefit, the manufacturer and the statutory health insurers negotiate a price. For drugs found to have no additional benefit, their ...
متن کاملPatient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany
UNLABELLED The German AMNOG healthcare reform includes a mandatory early-benefit-assessment (EBA) at launch. As per German social code, EBA is based on registration trials and includes evaluation of the patient-relevant effect of the new medicines compared to an appropriate comparator as defined by the Federal Joint Committee (G-BA). Current EBA decisions released have unveiled issues regarding...
متن کاملCONDITIONAL EXPECTATION IN THE KOPKA'S D-POSETS
The notion of a $D$-poset was introduced in a connection withquantum mechanical models. In this paper, we introduce theconditional expectation of random variables on theK^{o}pka's $D$-Poset and prove the basic properties ofconditional expectation on this structure.
متن کاملImpact of the Early Benefit Assessment on A Pharmaceutical's Real Consumption in Germany.
The Act on the Reform of the Market for Medicinal Products (“AMNOG”) introduced an early benefit assessment (EBA) of pharmaceuticals in Germany in 2011. According to this law, all pharmaceuticals with a new active agent made available on the market for the first time have to go through a benefit assessment process. A benefit assessment dossier has to be submitted at the time of the market entry...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2014
ISSN: 1098-3015
DOI: 10.1016/j.jval.2014.08.1161